<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01659242</url>
  </required_header>
  <id_info>
    <org_study_id>YK 01-2012</org_study_id>
    <nct_id>NCT01659242</nct_id>
  </id_info>
  <brief_title>Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis:an Ultrasound/Magnetic Resonance Imaging Study</brief_title>
  <official_title>Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis Patients With Active Disease Despite Methotrexate: an Ultrasound and Magnetic Resonance Imaging Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Singapore General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In rheumatoid arthritis patients with active disease despite optimal treatment with&#xD;
      methotrexate, the main objective of this pilot study is to use advance imaging tools such as&#xD;
      magnetic resonance imaging and ultrasound to evaluate which treatment option is more&#xD;
      efficacious: initiating methotrexate/sulfasalazine combination therapy, or switching to&#xD;
      leflunomide monotherapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>July 2012</start_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRI synovitis score</measure>
    <time_frame>four months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRI bone marrow edema score</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI erosion score</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>US synovitis score</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical outcomes</measure>
    <time_frame>4 months</time_frame>
    <description>Swollen/Tender joint counts, investigator's global assessment of disease activity (0-10), patient's assessment of disease activity (0-10), pain assessment by visual analogue scale (0-10), erythrocyte sedimentation rate, duration (mins) of early morning stiffness, and calculated disease activity indices</description>
  </secondary_outcome>
  <other_outcome>
    <measure>US erosion score</measure>
    <time_frame>4 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>US tenosynovitis score</measure>
    <time_frame>4 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>MRI tenosynovitis score</measure>
    <time_frame>4 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>4 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Methotrexate plus sulfasalazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ARM 1(Methotrexate(MTX) plus Sulfasalazine(SSZ))&#xD;
SSZ:Oral form, 2g/day, with escalation regime starting from 1g/day for the first week and increase to 1.5g/day in the next week and increasing to 2g/day by the third week. Total treatment period is 16 weeks. After reaching 2g/day, if patients conditions warrants (and no contraindication), SSZ may be increased at 0.5g per clinic visit) up to a maximum of 3g/day.&#xD;
MTX:Kept at the highest optimal dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leflunomide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ARM 2:Leflunomide(LEF)&#xD;
LEF: Oral form, 20mg every other day for first 2 weeks then increasing to 20mg per day by the third week. Total treatment period is 16 weeks.&#xD;
Methotrexate:Off</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate plus sulfasalazine</intervention_name>
    <description>ARM 1(Methotrexate(MTX) plus Sulfasalazine(SSZ))&#xD;
SSZ:Oral form, 2g/day, with escalation regime starting from 1g/day for the first week and increase to 1.5g/day in the next week and increasing to 2g/day by the third week. Total treatment period is 16 weeks. After reaching 2g/day, if patients conditions warrants (and no contraindication), SSZ may be increased at 0.5g per clinic visit) up to a maximum of 3g/day.&#xD;
MTX:Kept at the highest optimal dose.</description>
    <arm_group_label>Methotrexate plus sulfasalazine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leflunomide</intervention_name>
    <description>ARM 2:Leflunomide(LEF)&#xD;
LEF: Oral form, 20mg every other day for first 2 weeks then increasing to 20mg per day by the third week. Total treatment period is 16 weeks.&#xD;
Methotrexate:Off</description>
    <arm_group_label>Leflunomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Male and female patients aged between 21 and 65 years.&#xD;
&#xD;
          2. Patients with no childbearing potential (For example postmenopausal or sterilised) or&#xD;
             have decided not to have offspring(s).&#xD;
&#xD;
          3. All female patients must consent not to get pregnant/breastfeed, male patients must&#xD;
             consent not to father a child and all must consent to practice effective birth&#xD;
             control.&#xD;
&#xD;
          4. Fulfills either the 1987 ACR criteria and/or the 2010 ACR / EULAR RA Classification&#xD;
             Criteria.&#xD;
&#xD;
          5. Seropositivity: Rheumatoid factor (RF) and/or anti -cyclic citrullinated protein&#xD;
             antibodies (anti-CCP) must be positive.&#xD;
&#xD;
          6. MCPJ(s) and/or Wrist(s) joint(s) involvement.&#xD;
&#xD;
          7. Rheumatoid arthritis patients (less than 5 years duration) who remain at least&#xD;
             moderately active based on DAS28 score of &gt; 3.2, following 3 months of therapy with an&#xD;
             optimal dose of methotrexate(e.g. at least 15 mg/week).&#xD;
&#xD;
          8. If patient is on oral corticosteroids, this should not exceeding 10mg prednisolone&#xD;
             daily (or oral steroid equivalent) for at least 4 weeks and should be at an unchanged&#xD;
             dose for at least 2 weeks before entering study.&#xD;
&#xD;
          9. If patient is on NSAIDs, this should be at an unchanged dose for at least 2 weeks&#xD;
             before entering study.&#xD;
&#xD;
         10. Glomerular filtration rate &gt; 60 mls/min/1.73m2.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Patient known to have the following medical condition(s) will be excluded:&#xD;
&#xD;
               1. Other autoimmune disease /inflammatory joint disease/connective tissue disease (&#xD;
                  e.g. lupus, seronegative spondylarthropathy (e.g. ankylosing&#xD;
                  spondylitis/psoriatic arthropathy ), reactive arthritis, overlap syndrome,&#xD;
                  primary sjogren syndrome and mixed connective tissue disease.)&#xD;
&#xD;
               2. Inflammatory arthritis with onset before 18 years old.&#xD;
&#xD;
               3. Current or previous history of cancer or lymphoproliferative disease.&#xD;
&#xD;
               4. HIV positive status, Hepatitis B/C positive status.&#xD;
&#xD;
               5. Persistent and/or severe infection in the previous 12 weeks.&#xD;
&#xD;
               6. Major traumatic injury, terminal illness, or other medical condition(s)that could&#xD;
                  place the patient at risk to participate in the study.&#xD;
&#xD;
               7. Clinically relevant cardiovascular (e.g unstable ischemic heart disease),&#xD;
                  neurological (e.g recent stroke), gastroenterology (e.g active peptic ulcer&#xD;
                  disease), renal (e.g chronic renal failure), hepatic (e.g alcoholic liver&#xD;
                  disease, fatty liver) and any other major systemic disease that could i) place&#xD;
                  the patient at risk to participate in the study; or ii) make protocol&#xD;
                  implementation difficult; or iii) make study results interpretation difficult.&#xD;
&#xD;
               8. Presence of any known condition(s)/circumstance(s) which would negatively impact&#xD;
                  compliance or study completion.&#xD;
&#xD;
          2. Impaired laboratory parameters:&#xD;
&#xD;
               1. Hemoglobin less than 10.5 g/dl, white blood count less than 4 x 10 (9)/L ,&#xD;
                  platelet count less than 150 x 10(9)/L.&#xD;
&#xD;
               2. Deranged Liver function test: e.g. elevated AST/ALT.&#xD;
&#xD;
          3. Wants to consume alcohol while taking the study medications.&#xD;
&#xD;
          4. Body weight that is less than 45 kg.&#xD;
&#xD;
          5. Pregnancy/Breastfeeding/Male patient wishing to father children.&#xD;
&#xD;
          6. Patients with the following medication history will be excluded:&#xD;
&#xD;
               1. History of Glucose 6 Phosphate Dehydrogenase (G6PD) deficiency.&#xD;
&#xD;
               2. Known allergy to: i) study medications; or ii) contrast; or iii) drugs whose&#xD;
                  chemical structures are similar (e.g. sulphonamides, salicylates, etc).&#xD;
&#xD;
               3. On anticoagulation for any reasons.&#xD;
&#xD;
               4. Previous treatment (within the last 4 weeks) with: i) oral corticosteroid greater&#xD;
                  than prednisolone equivalent of 10mg/day; or ii) parenteral/intra-articular&#xD;
                  corticosteroid injection.&#xD;
&#xD;
               5. Previous treatment (within the last 12 weeks) with: i) other DMARDs such as&#xD;
                  sulfasalazine,hydroxychloroquine,chloroquine,gold salts, etc; or ii)&#xD;
                  investigational drug(s); or iii) other immunosuppressive agents such as&#xD;
                  cyclophosphamide,cyclosporin,azathioprine and any biologic agents, e.g. anti-TNF.&#xD;
&#xD;
               6. Previous treatment(any duration) with i) Leflunomide; or ii) Sulfasalazine used&#xD;
                  together with methotrexate&#xD;
&#xD;
          7. Contraindication to MRI (e.g. pacemakers, metallic implants/stents, claustrophobia).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>York Kiat Tan, MBBS,MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Singapore General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>August 3, 2012</study_first_submitted>
  <study_first_submitted_qc>August 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2012</study_first_posted>
  <last_update_submitted>November 26, 2014</last_update_submitted>
  <last_update_submitted_qc>November 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>Ultrasound</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulfasalazine</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Leflunomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

